TABLE 6.
PROs Stratified by AE Status
| Questionnaire | AE status | Baseline | 3 months | 12 months |
|---|---|---|---|---|
| EQ-5D Mean (SD) |
No AE | 0.61 (0.20) | 0.67 (0.13) | 0.73 (0.12) |
| Any AE | 0.61 (0.19) | 0.63 (0.14) | 0.67 (0.16) | |
| SF36 Physical Mean (SD) |
No AE | 40.26 (11.46) | 39.44 (9.55) | 44.65 (10.22) |
| Any AE | 37.73 (12.61) | 35.96 (10.02) | 39.29 (11.85) | |
| SF36 Mental Mean (SD) |
No AE | 45.48 (13.03) | 49.53 (11.28) | 50.78 (11.07) |
| Any AE | 44.96 (12.94) | 48.41 (11.05) | 50.33 (12.07) | |
| SOSGOQ Mean (SD) |
No AE | 0.72 (0.18) | 0.72 (0.16) | 0.80 (0.13) |
| Any AE | 0.68 (0.19) | 0.67 (0.18) | 0.73 (0.18) |
AE, adverse event; EQ-5D, EuroQol 5D; SF-36, Short-Form 36; SOSGOQ, Spine Oncology Study Group Outcomes Questionnaire.
Change from baseline was significantly different according to the AE status with results highlighted in bold (any AE = 0.05 vs no AE = 0.13) (P = .047).
Baseline and 12-month data refer to cohort with follow-up up to 12 months. Three-month data refer to patients with a follow-up up to 3 months.